Sign In to Follow Application
View All Documents & Correspondence

Cyclic Compounds As Dipeptidyl Peptidase Iv Inhibitors

Abstract: Described are novel compounds of the formula (I), their derivatives, analogs,tautomeric  forms,regioisomers,stereoisomers,polymorphs,  solvates,intermediates,pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose,serum insulin,free fatty acids, cholesterol, triglyceride levels; treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis, rheumatoid arthritis; treatment and/or prophylaxis of type II diabetes. These compounds are more particularly dipeptidyl peptidase (DPP IV) inhibitors.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
09 January 2009
Publication Number
21/2011
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2015-10-20
Renewal Date

Applicants

ORCHID RESEARCH LABORATORIES LTD.
ORCHID TOWERS, 313, VALLUVAR KOTTAM HIGH ROAD, NUNGAMBAKKAM, CHENNAI - 600 034

Inventors

1. BALASUBRAMANIAN GOPALAN
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
2. SAKAMURI SUKUMAR
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
3. SINGH GAJENDRA
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
4. DHARMALINGAM SIVANESAN
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
5. POOPPADY XAVIER FRANKLIN
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
6. NARAYANANA SHRIDHAR
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
7. MOOKKAN JEYAMURUGAN
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
8. BALASUBRAMANIAN JEGANATHA SIVAKUMAR
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
9. RAJALINGAM AGNEESWARI
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.
10. KULATHINGAL JAYANARAYAN
ORCHID RESEARCH LABORATORIES LTD. 476/14, OLD MAHABALIPURAM ROAD, SHOLINGANALLUR, CHENNAI - 600 119.

Specification

We Claim:

1, Compound of formula (I),

their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof; wherein Y represents -0-, -S(0)p-, -CH2-» -CHOH-, -CHF- or -CF2-; m, n and p are integers independently selected from 0, 1, or 2; X represents a bond, C1-C5 aIkyleneor-C(=0)-;

R1 represents hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heterocyciyl, heterocycloalkyl, heterocyclylalkyi, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -N3, -S(O)pRi0, -NR10S(O)pRn, -CN, -COOR10, -CONR10Rn, -OR10, -NR,0RU or~NRl0CORu or a group selected from:

wherein R12 represents hydrogen or substituted or unsubstituted groups selected from alkyl, alkoxy, acyl, hydroxylalkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic ring, heterocycloalkyl heterocyclylalkyi, heteroarylalkyl, carboxylic acid or carboxylic acid derivatives selected from esters, amides, acid halides, hydroxamic acid and hydroxamates;

R2, R3 and R4 independently represents hydrogen, hydroxy, halogen, alkyl, haloalkyl, cyano, hydroxyalkyl, alkoxy, alkylsulfonyl, alkylthio, phenyl-S(0)p-alkyl, amino, -NRloRn or phenylalkyl, wherein said phenyl is optionally substituted independently with one or more alkyl, cycloalkyl, alkoxy, cyano, halogen, alkylsulfonyl, alkylthio, -CC^alkyl, -COOH, -CONH2, -CHO, -CH2OH, hydroxy!, haloalkyl, amino, nitro or R2 and R4 can be combined together to form an optionally substituted 4-10 membered ring having 0-4 hetero atoms selected from N, O and S;

R5 represents hydrogen or optionally substituted alkyl group;

R6 represents hydrogen or optionally substituted groups selected from alkyl, alkoxyalkyl,
hydroxyalkyl, amino, R^alkyl and R^C(NH)NHalkyl;
R and R independently represents hydrogen, alkyl or hydroxyl;

R8 is hydrogen, cyano, COOH, or an isosterate of a carboxylic acid comprising SO3H, B(OH)2, PO3R10Rn, SO2NR10Rn, tetrazole, -COOR10, *CONR10RM, -NR10CORU and -COOCOR10;

R10 and Ru independently represents hydrogen, nitro, hydroxy, cyano, formyl, acetyl, halogen or optionally substituted groups selected from amino, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclyl, heterocycloalkyl, heterocyclylalkyl, heteroarylalkyl or a carboxylic acid or carboxylic acid derivatives selected from esters, amides, acid halides, hydroxamic acid and hydroxamates;

when the groups R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are substituted or when the term "substituted" is used, the substituents are one or more and are selected from halogens, hydroxy, nitro, cyano, azido, nitroso, oxo (=0), thioxo (=S), thioalkyl, amino, hydrazino, formyl, alkyl, haloalkyl group, alkoxy, haloalkoxy, arylalkoxy, cycloalkyl, cycloalkyloxy, aryl, heterocycloalkyl, heteroaryl, alkylamino, tolyl, -COORa, -C(0)Ra, -C(S)Ra, -C(0)NRaRb, -C(S)NRaRb, -NR^^NR^0, -NRaC(S)NRbRc, -N(Ra)SORb, -N(RB)S02R\ -NR8C(0)ORb, -NRflRb, -NRaC(0)Rb, -NRflC(S)Rb, -SONRaRb, -S02NRaRb, -ORfl, -0R8C(0)0Rb, -OC(0)NRaRb, -OC(0)Ra, -R'NR1^, -RflORb, -SRa, -SORa and -S02Ra; the substituents are further optionally substituted by one or more substituents as defined above;

wherein Ra, Rb and Rc independently represents hydrogen or substituted or unsubstituted groups selected from alkyl, alkylene, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, cycloalkyl and cylcoalkenyl; or RB and Rb can be combined together to form a ring structures having 4-8 atoms.

2. The compound according to claim 1, wherein: when alkoxy group is present, the alkoxy group is selected from methoxy, ethoxy, n-propoxy, isopropoxy, n»butoxy, isobutoxy and t-butoxy; when aryloxy group is present, the aryloxy group is selected from phenoxy and naphthyloxy; when halogen is present, the halogen is fluorine, chlorine, bromine or iodine; when alkyl group is present, the alkyl group is methyl, ethyl, n-propyl, isopropyl, butyl,isobutyl, /-butyl, pentyl, hexyl, heptyl or octyl; when alkenyl group is present, the alkenyl group is ethenyl, 1-propenyl, 2-propenyl, iso-propenyl, 2-methyl-l-propenyl, 1-butenyl or 2-butenyl; when the alkynyl group is present, the alkynyl group is ethynyl, propynyl or butynyl; when cycloalkyl group is present, the cycloalkyl group is cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, perhydronaphthyl, adamantyl, bridged cyclic groups or spirobicyclic groups; when cycloalkenyl group is present, the cycloalkenyl group is selected from cyclopentenyl and cyclohexenyl; when heterocycloalkyl or heteroaryl group is present, the heterocycloalkyl or heteroaryl group is a heterocyclyl group selected from azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl,phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl, purinyl, quinazolinyl,quinoxalinyl, quinolinyl, isoquinolinyl, tetrazolyl, imidazolyl, tetrahydroisoquinolinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, piperonyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl,oxazolyl, oxazolinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl,
thiazolidinyl, thienyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl,indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, decahydroisoquinolyl,benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzothiadiazolyl,benzoxadiazolyl, benzotriazolyl, benzothienyl, benzoxazolyl, oxadiazolyl, benzindazolyl,indazolyl, phenylpiperidinyl, furyl, tetrahydrofuryl, tetrahydropyranyl, piperazinyl,homopiperazinyl, piperidyl, piperidopiperidyl, morpholinyl, thiomorpholinyl, piperidonyl, 2-oxopiperazinyl, 2-oxopiperidinyI, pyrrolidinyl, 2-oxopyrrolidinyl, oxazolidinyl, chromanyl, isochromanyl,oxabicyclo[3.2.1]octane,3-oxabicyclo[3.2.1]octanone,3-azabicyclo[3.2.1]octane-2,4-dione and 3-azabicyclo[3.2.1]octaoe; when aryl group is present,the aryl group is phenyl, naphthyl, anthracenyl, indanyl or biphenyl; when alkylene group is present, the alkylene group is methylene, ethylene, propylene or butylene; when hydroxyalkyl group is present, the hydroxyalkyl group is hydroxymethyl or hydroxyethyl; when haloalkyl group is present, the haloalkyl group is trifluoromethyl, tribromomethyl or trichloromethyl;when haloalkoxy group is present, the haloalkoxy group is selected from chloromethoxy,chloroethoxy, trifluoromethoxy, trifluoroethoxy and trichloromethoxy; when
heterocyclylalkyl group is present, the heterocyclylalkyl group is selected from
oxadiazolylmethyl,triazolylmethyl,tetrazolylmethyl,morpholinylmethyl,pyrrolidinylmethyl, piperidinylmethy 1,1,2-thiazinane 1 ,1 -dioxide-ylmethyl and isothiazolidine 1,1 -dioxide-ylmethyl; when heteroarylalkenyl group is present, the heteroarylalkenyl group is selected from pyridinylethenyl,thienylethenyl and triazolylethenyl; and when heteroarylalkynyl group is present, the heteroarylalkynyl group is
selected from pyridinylethynyl, thienylethynyl and triazolylethynyl.

3. A compound of formula (I), as claimed in claim 1, which is selected from:

1. (2S,4S)-l-(2-((lR,3S)-3-((lH-l,2,4-TriazoM-yl)methyl)-l,2,2-
trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

2. (2S,4R)-l-(2-((lR,3S)-3-((lH-l,2J4-Triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile methanesulfonate;

3. (2S,4S)-l-(2-((lS,3R)-3-((lH-l,2,4-Triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

4. (2S,4S)-l-(2-((lS,3R)-3-((lH-l,2,4-Triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile methanesulfonate;

5. (2S,4R)-l-(2-((lS)3R)-3-((lH-l12]4-Triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrroIidine-2-carbonitrile methanesulfonate;

6. (S)-l-(2-((lS,3R)-3-((lH-l,2,4-Triazol-l-yl)methyl)-l)2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

7. (S)-l-(2-((lS,3R)-3-((lH-l,2,4-Triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile methanesulfonate;

8. (S)-l-(2-((lR,3S)-3-((lH-l,2,4-Triazol-l-yI)methyl)-lJ2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

9. (S)-l-(2-((1R,3S-H-l^-Triazol-l-yl)methyl)-1,2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile methanesulfonate;

10. (2S,4S)-l-(2-((lR,3S)-3-((2H-l,2,3-Triazol-2-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyI)-4-fluoropyrrolidine-2-carbonitrile;

11. (2S)4S)-l-(2-((lR,3S)-3-((lH-l,2,3-TriazoI-l-yl)methyl)-l)2)2-
trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

12. (2S,4S)-l-(2-((lS,3R)-3-((2H-l,2,3-TriazoI-2-yl)methyl)-lJ2t2-trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

13. (2SJ4S)-l-(2-((lS,3R)-3-((lH-l,2,3-Triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile methanesulfonate;

14. (2S,4S)-4-Fluoro-l-(2-((lR)3S)-l,2,2-trimethyl-3-(piperidine-l-carbonyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

15. (2S,4S)-4-Fluoro-I-(2-((lR,3S)-3-((4-(hydroxymethyl)-lH-l,2,3«triazol-l-yl)methyl)-l,2,24rimethylcyclopentylamino)acetyl)pyrroHdine-2-carbonilrile;

16. (2S,4S)-4-Fluoro-l-(2-((lS33R)-3-((4-(hydroxymethyl)-lH-l,2,3-triazol-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyI)pyrroIidine-2-carbonitrile;

17. N-(((lS,3R)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrrolidin-l-yl)-2-oxoethylamino)-2s2,3-trimethylcycIopentyl)methyl)methanesulfonamide;

18. N-(((lR,3S)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrTolidin-l-yl)-2-oxoethylamino)-2,2,3-trimethylcyclopentyl)methyl)methanesulfonamide;

19. N-(((lS,3R)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrrolidin-l-yl)-2-oxoethylamino)-2,2,3-trimethylcyclopentyl)methyl)-4-fluorobenzenesulfonamide;

20. N-(((lR,3S)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrrolidin-l-yl)-2-oxoethylamino)-2,2,3-trimethylcyclopentyl)methyl)-4-fluorobenzenesulfonamide;

21. N-(((lS,3R)-3-(2-((2S)4S)-2-Cyano-4.fluoropyrrolidin-l-yl)-2-oxoethylamino)-2,2,3-trimethylcyclopentyl)methyl)-2-fluorobenzamide;

22. N-(((lSJ3R)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrrolidin-l-yl).2-oxoethylamino)-2J2)3-trimethylcyclopentyl)methyl)-4,4-difluorocyclohexanecarboxamide;

23. N-(((lR(3S)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrrolidin-l-yl)-2-oxoethylamino)-2,2,3-trimethylcyclopentyl)methyl)-4,4-difluorocycIohexanecarboxamide;

24. 6<((lS(3R)-3-(2-((2SJ4S)-2-Cyano-4-fluoropyrroltdin-l-yl)-2-oxoethylammo)-2,2,3-trimethylcyclopentyl)methylamino)nicotinonitrile;

25. 6-(((lR,3S)-3-(2-((2S,4S)-2-Cyano-4-fluoropyrrolidin-l-yl)-2-oxoethylamino)-2)2J3-trimethylcyclopentyl)methylamino)nicotinonitrile;

26. 2-(((lS,3R)-3-(2-((2S,4S)-2-Cyano-4-fluoropynx)Hdiii-l-yl)-2-oxoethyIamino)-2,2J3-trimethylcyclopentyl)methylamino)nicotinonitrile;

27. (2S,4S)-4-FIuoro-l-(2-((lR,3S)-l,2,2-trimethyl-3-((5-(trifluoromethyI)pyridin-2-ylamino)methyl)cyclopentylamino)acetyl)pyrroliditte-2-carbonitrile;

28. (2St4S)-l-(2-((lR,3S)-3-t(l)l-Dioxidoisothiazolidin-2-yl)methyl]-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrroIidine-2-carbonitrile;

29. (2S,4S)-l-(2-((lS,3R)-3-[(l,l-Dioxidoisothiazolidin-2-yl)methyl]-lt2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyrroIidine-2-carbonitrile;

30. (2SJ4S)-l-(2-((lS,3R)-3-[(l!l-Dioxido-l,2-thiazinan-2-yl)methyl]-l,2(2-trimethylcyclopentylamino)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

31. (2S,4S)-1,2-((lR,3S)-3-((lH-Tetrazol-l-yI)methyl)-l,2>2-trimethylcyclopentyI
amino)acetyl)-4-fluoropyrrolidine-2-carbonitrilemethanesulfonate;

32. (2S,4S)-l-(2.((lS53R)-3-((lH-TetrazoI-l-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)-4-fluoropyn,olidine-2-carbonitrile;.

33. (2S,4S)-4-Fluoro-l-(2-((lR,3S)-l,2,24rimethyl-3-(morpholinomethyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitriIe;

34. (2S,4S)-4-Fluoro-l-(2-((lS,3R)-l)2J2-trimethyl-3-(morpholinomethyI)cyclopentylamino)acetyl)pyrroIidine-2-carbonitrile;

35. (2SJ4S)-4-Fluoro4-(2-((lS)3R)-l,2,2-trimethyl-3-(morpholinomethyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitriledimethanesulfonate;

36. (2S,4S)-4-Fluoro-l-(2-((lR)3S)-l,2,2-trimethyl-3-(pyrrolidin-l-ylmethyl)cyclo pentylamino)acetyl)pyrrolidine-2-carbonitrile;

37. (2SJ4S)-4-Fluoro-l-(2-((lSJ3R)-lJ2)2-trimethyl-3-(pyrroIidin-l-ylmethyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

38. (2S,4SH-Fluoro-l-(2-((lRJ3S)-3-(((R)-3-hydroxypym)lidin-l-yl)methyl)-l- trimethylcyclopentylamino)acetyl)pyiTolidine-2-carbonitrile;

39. (2S,4S)-4-Fluoro-l-(2-((lR(3S)-l,2,2-trimethyI-3-(piperidin-l-ylmethyl)cycIopentylamino)acetyl)pyrrolidine-2-carbonitrile;

40. (2S,4S)-4-Fluoro-l-(2-((lS,3R)-lJ212-trimethyl-3-(piperidin-l-ylmethyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

41. (2S,4S)-Fluoro-l-(2-((lR,3S)-3K(4-hydroxypiperidin-l-yI)methyl)-lJ2-2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

42. (2S,4S)-4-Fluoro-l-(2-((lR,3S)-l,2,2-trimethyl-3-((4-(methylsulfonyl)phenylsulfonyl)methyl)cyclopentylamino)acetyl)pyrroiidine-2-carbonitrile;

43. (2S,4R)-4-Fluoro-l-(2-((lR,3S)*lJ2)2-trimethyl-3-((4-(methylsulfonyl)phenylsulfonyl)methyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

44. (S)-l-(2-((lR,3S)-l52,2-TrimethyI-3-((4-(methylsulfonyI)phenylsulfonyl)methyI)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

45. (2S,4S)-4-Fluoro-l-(2«lS,3R)-l,2,2-trimethyl-3-((4-(methylsulfonyl)phenylsulfonyl)methyl)cyclopentylamino)acetyl)pyrroHdine-2-carbonitrile;

46. (S)-1 -(2-((l S,3R)» 1 ,2,2-Trimethyl-3-((4-(methylsulfonyl) phenylsulfonyl)methyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

47. (2St4R)-4-F]uoro-l-(2-((lS,3R)-l12,2-trimethyl-3-((4-(methylsulfonyl)phenylsulfonyl)methyl)cyclopentyIamino)acetyl)pyrrolidine-2-carbonitrile;

48. (2S,4S)-4-Fluoro-l-(2-((lR(3S)-3-(3-(4-fluorophenyl)-l,2,4-oxadiazol-5-yl)-i,2,2-trimethylcyclopentyIamino)acetyl)pyrrolidine-2-carbonitrile;

49. (2S,4S)-4-Fluoro-l-(2-((lSJ3R)-3-(3-(4-fluorophenyl)-l)2J4-Oxadiazol-5-yl)-l,2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

50. (2S,4S)-4-Fluoro-l-(2-((lR,3S)-l,2)2-trimethyl-3-(3-methyl-l,2,4-oxadiazoI-5-yl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

51. (2S,4S)-4-FIuoro-l-(2-((lSJ3R)-l)2,2-trimethyl-3-(3-methyl-l)2J4-oxadiazol-5-yl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

52. (2S,4S)-4-Fluoro-l-(2-((lR,3S)-3-(3-isopropyI-lJ2J4-oxadiazol-5.yl)-l,2,2-trimethylcyclopentylamino)acetyl)pyrroIidine-2-carbonitrile;

53. (2S)4S)-l-(2-((lR»3R)-3-(Cyanomethyl)-l)2t2-trimethylcyclopentyl amino)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

54. (2S,4S)*4-Fluoro-l-(2-((lRJ3R)-l,2,2-trimethyl-3-((5-metiiyI-l)2)4-oxadiazol-3-yl)methyl)cyclopentylamino)8cetyl)pyrrolidine-2-carbonitriIe;

55. (2S,4S)-4-Fluoro-l-(2-((lS,3S)-l,2,2-trimethyl-3-((5-methyl-l,2)4-oxadiazoi-3-yl)methyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

56. (2S,4S)^4-Fluoro-l-(2-((lS)3S)-l)2)2-trimethyl-3-((5-(trifluoromethyl)-lJ2)4-oxadiazol-3-yl)methyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

57. (2S,4S)-4-Fluoro-l-(2-((lSJ3S)-lJ2)2-trimethyl-3-((5Ktrifluoromethyl)-lJ2)4-oxadiazol-3-yl)methyI)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile methanesulfonate;

58. (2SJ4S)-l-(2-((lS,3S)^3-((5-/e«-Butyl-l,2>4-oxadiazol-3-yI)methyl)-l,2,2-trimethylcyclopentyIamJno)acetyl)-4-fluoropyrrolidine-2-carbonitrile;

59. (2S,4S)-l-(2-((lS,3S)-3-((5.Cyclohexyl-l(2s4-oxadiazoN3-yl)methyl)-l,2,2-trimethylcycIopentylamino)acetyl)-4-fluoropyrroIidine-2-carbonitrile;

60. (2S,4S)^-F]uoro-K2-aiS,3S)-3™((5-(hydroxymethyl)-lJ2)4-oxadiazol-3-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

61. (2SJ4S)-4-Fluoro-l-(2-((lS,3S)-3-((5-isopropyl-l,2J4-oxadiazol-3-yl)methyl)-l,2J2-
trimethylcyclopentylamino)acetyl)pyrroIidine-2-carbonitrile methanesulfonate;

62. (2S,4S)-4-Fluoro-l-(2-((lSJ3S)-3-((5-(4-fluorophenyl)-l»2,4-oxadia2ol-3-yl)methyl)-l,2,2-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

63. (2S,4S)-4-Fluoro-l-(2-((lS,3S)-l)2)2-trimethyI-3-((5-(pyridin-4*yl)-l,2,4-oxadiazoI-3-yl)methyl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

64. (2S,4S)-4-Fluoro-l-(2-((lR,3S)-3-(3-(4-fluorophenyl)-l,2,4-oxadiazol-5-yl)-2t2,3-trimethylcyclopentylamino)acetyl)pyrroIidine-2-carbonttrile

65. (2SJ4S)-4-Fluoro-l-(2*((lS,3R)-3-(3-(4-fluorophenyl)4,2,4-oxadiazol-5-yl)-2,2,3-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

66. (S)-l-(2-((lS,3R)-3-(3-(4-Fluorophenyl)-l,2,4-oxadiazol-5-yl)-2J2,3-
trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrilemethane$ulfonate;

67. (2S,4S)-4-Fluoro-l-(2-((lS,3R)-3-(3-isopropy]-l,2,4-oxadiazol-5-yl)-2,2,3-trimethylcyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

68. (2S,4S)-4-Fluoro-l-(2-((lSJ3R)-2,2,3-trimethyl-3-(3-(pyridin-3-yl)-l,2,4-oxadiazol-5-yl)cyclopentylamino)acety|)pyrrolidine-2-carbonitrile;

69. (2SJ4S)-4-FIuoro-l-(2-((lR>3S)-2,2,3-lT!methyl-3-(3-(pyridin-3-yl)-l>2(4-oxadiazol-5-yI)cyclopentylamino)acetyl)pyrrolidine-2-oarbonitrile;

70. (2S,4S)-4-Fluoro-l-(2-((lS,3R)-2t2)3-trimethyl-3-(3-(pyridin-4-yl)-l>2J4-oxadiazol-5-yl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitriIe;

71. (2SJ4S)-4-FIuoro-l-(2-((lR,3S)-2,2,3-trimethyl-3-(3-(pyridin-4-yl)-l,2,4-oxadiazol-S-yOcyclopentylaminoJacetyOpyiTolidine^-carbonitrile;

72. (2SJ4S)-4-Fluoro-l-(2-((lS,3R)-2,2J3-trimetbyl-3-(3-(pyrazin-2-yl)-l,2,4-oxadiazol-5-yl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

73. (2S,4S)-4-Fluoro-l-(2-((lR)3S)-2J2,3-trimethyl-3-(3-methyl-l,2,4-oxadiazol-5-yl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

74. (2S,4S)-4-Fluoro-l-(2-((lS,3R)-2,2(3-trimethyl-3-(3-methyl-l>2,4-oxadiazol-5-yl)cyclopentylamino)acetyl)pyrrolidine-2-carbonitrile;

75. (S)-l-(2-((lR,5R)-3,5J8,8-Tetramethyl-2J4-dioxo-3-azabicyclo[3.2.1]octan-l-
ylamino)acetyl)pyrrolidine-2-carbonitrile;

76. (2S,4S)-4-Fluoro-l-(2-((lR,5R)-3,5,8,8-tetramethyl-3-azabicyclo[3.2.1]octan-l-ylamino)acetyl)pyrroUdine-2-carbonitrile;

77. (2S,4R)-4-Fluoro-l-(2-((lR,5R)-3,5,8,8-tetramethyl-3-azabicyclo[3.2.1]octan-l-ylamino)acetyl)pyrroIidine-2-carbonitrile;

78. (S)-1-(2-((1R,5R)-3,5,8,8-Tetramethyl-S-azabicyclotS^.lloctan-l-
ylamino)acetyl)pyrrolidine-2-carbonitrile;

79. (S)-l-(2-((lR,5R)-5,8)8-Trimethyl-2-oxo-3-oxabicyclo[3.2.1]octan-l-ylamino)acetyl)pyrrolidine-2-carbonitrile;

80. (S)-l-(2-((lR,5R)-5J8t8-Trimethyl-3-oxabicyclo[3.2.1]octan-l-yIamino)acetyl)pyrrolidine-2-carbonitrile;

81. (2S,4S)-4-Fluoro-l-(2-((lR,5R)-5,8,8-trimethyl-3-oxabicyclo[3,2fl]octan-l-ylamino)acetyl)pyrrolidine-2-carbonitrile;

82. (2S,4S)-4-FIuoro-l-(2-((lS,5S)-5)8,8-trimethyl-3-oxabicyclo[3.2.1]octan-l-ylamino)acetyl)pyrroIidine-2-carbonitrile;and

83. (2SJ4S)-l-(2"((lS,3R)-3-(3-(lH-l)2,4-TriazoM-yl)propyl)-2)2t3-trimethylcyclopen

Documents

Orders

Section Controller Decision Date

Application Documents

# Name Date
1 65-che-2009 form-5 07-01-2010.pdf 2010-01-07
1 65-CHE-2009-Correspondence_06-03-2020.pdf 2020-03-06
2 65-CHE-2009-Form27_License_06-03-2020.pdf 2020-03-06
2 65-CHE-2009 FORM-2 07-01-2010.pdf 2010-01-07
3 Correspondence by Applicant_Form27_22-02-2019.pdf 2019-02-22
3 65-che-2009 description(complete) 07-01-2010.pdf 2010-01-07
4 Form27_Working of the Patented Invention_22-02-2019.pdf 2019-02-22
4 65-che-2009 correspondence others 07-01-2010.pdf 2010-01-07
5 Correspondence by Applicant_Renewal Fees_31-12-2018.pdf 2018-12-31
5 65-che-2009 claims 07-01-2010.pdf 2010-01-07
6 Correspondence by Applicant_Form27_16-02-2018.pdf 2018-02-16
6 65-che-2009 abstract 07-01-2010.pdf 2010-01-07
7 Form27_License_16-02-2018.pdf 2018-02-16
7 65-CHE-2009 FORM-3 18-01-2010.pdf 2010-01-18
8 Correspondence by Applicant_Renewal fee_04-01-2018.pdf 2018-01-04
8 65-CHE-2009 FORM-18 08-07-2010.pdf 2010-07-08
9 Correspondence by Applicant_Form27_22-03-2017.pdf 2017-03-22
9 65-che-2009 form-3 06-09-2010.pdf 2010-09-06
10 0065-che-2009 form-1.pdf 2011-09-02
10 Form27_License_22-03-2017.pdf 2017-03-22
11 0065-che-2009 description(provisional).pdf 2011-09-02
11 Correspondence by Applicant_Renewal fee_29-12-2016.pdf 2016-12-29
12 0065-che-2009 correspondence-others.pdf 2011-09-02
12 65-CHE-2009_EXAMREPORT.pdf 2016-07-02
13 0065-che-2009 abstract.pdf 2011-09-02
13 65-CHE-2009-Abstract-300915.pdf 2015-10-05
14 65-CHE-2009 FORM-3 12-10-2011.pdf 2011-10-12
14 65-CHE-2009-Claims-300915.pdf 2015-10-05
15 65-CHE-2009 CORRESPONDENCE OTHERS 12-10-2011.pdf 2011-10-12
15 65-CHE-2009-Correspondence-300915.pdf 2015-10-05
16 65-CHE-2009 FORM-3 27-03-2012.pdf 2012-03-27
16 65-CHE-2009-Correspondence-090915.pdf 2015-09-11
17 65-CHE-2009 FORM-6 05-10-2012.pdf 2012-10-05
17 65-CHE-2009-Form 3-090915.pdf 2015-09-11
18 65-CHE-2009 AMENDED PAGES OF SPECIFICATION 30-04-2015.pdf 2015-04-30
18 65-CHE-2009 FORM-3 28-01-2013.pdf 2013-01-28
19 65-CHE-2009 FORM-3 23-08-2013.pdf 2013-08-23
19 65-CHE-2009 AMENDED CLAIMS 30-04-2015.pdf 2015-04-30
20 65-CHE-2009 FORM-1 30-04-2015.pdf 2015-04-30
20 65-CHE-2009 CORRESPONDENCE OTHERS 23-08-2013.pdf 2013-08-23
21 65-CHE-2009 FORM-3 30-04-2015.pdf 2015-04-30
21 65-CHE-2009 EXAMINATION REPORT REPLY RECEIVED 30-04-2015.pdf 2015-04-30
22 65-CHE-2009 FORM-5 30-04-2015.pdf 2015-04-30
22 65-CHE-2009 OTHERS 30-04-2015.pdf 2015-04-30
23 65-CHE-2009 FORM-5 30-04-2015.pdf 2015-04-30
23 65-CHE-2009 OTHERS 30-04-2015.pdf 2015-04-30
24 65-CHE-2009 FORM-3 30-04-2015.pdf 2015-04-30
24 65-CHE-2009 EXAMINATION REPORT REPLY RECEIVED 30-04-2015.pdf 2015-04-30
25 65-CHE-2009 CORRESPONDENCE OTHERS 23-08-2013.pdf 2013-08-23
25 65-CHE-2009 FORM-1 30-04-2015.pdf 2015-04-30
26 65-CHE-2009 AMENDED CLAIMS 30-04-2015.pdf 2015-04-30
26 65-CHE-2009 FORM-3 23-08-2013.pdf 2013-08-23
27 65-CHE-2009 AMENDED PAGES OF SPECIFICATION 30-04-2015.pdf 2015-04-30
27 65-CHE-2009 FORM-3 28-01-2013.pdf 2013-01-28
28 65-CHE-2009 FORM-6 05-10-2012.pdf 2012-10-05
28 65-CHE-2009-Form 3-090915.pdf 2015-09-11
29 65-CHE-2009 FORM-3 27-03-2012.pdf 2012-03-27
29 65-CHE-2009-Correspondence-090915.pdf 2015-09-11
30 65-CHE-2009 CORRESPONDENCE OTHERS 12-10-2011.pdf 2011-10-12
30 65-CHE-2009-Correspondence-300915.pdf 2015-10-05
31 65-CHE-2009 FORM-3 12-10-2011.pdf 2011-10-12
31 65-CHE-2009-Claims-300915.pdf 2015-10-05
32 0065-che-2009 abstract.pdf 2011-09-02
32 65-CHE-2009-Abstract-300915.pdf 2015-10-05
33 0065-che-2009 correspondence-others.pdf 2011-09-02
33 65-CHE-2009_EXAMREPORT.pdf 2016-07-02
34 0065-che-2009 description(provisional).pdf 2011-09-02
34 Correspondence by Applicant_Renewal fee_29-12-2016.pdf 2016-12-29
35 0065-che-2009 form-1.pdf 2011-09-02
35 Form27_License_22-03-2017.pdf 2017-03-22
36 65-che-2009 form-3 06-09-2010.pdf 2010-09-06
36 Correspondence by Applicant_Form27_22-03-2017.pdf 2017-03-22
37 Correspondence by Applicant_Renewal fee_04-01-2018.pdf 2018-01-04
37 65-CHE-2009 FORM-18 08-07-2010.pdf 2010-07-08
38 Form27_License_16-02-2018.pdf 2018-02-16
38 65-CHE-2009 FORM-3 18-01-2010.pdf 2010-01-18
39 Correspondence by Applicant_Form27_16-02-2018.pdf 2018-02-16
39 65-che-2009 abstract 07-01-2010.pdf 2010-01-07
40 Correspondence by Applicant_Renewal Fees_31-12-2018.pdf 2018-12-31
40 65-che-2009 claims 07-01-2010.pdf 2010-01-07
41 Form27_Working of the Patented Invention_22-02-2019.pdf 2019-02-22
41 65-che-2009 correspondence others 07-01-2010.pdf 2010-01-07
42 Correspondence by Applicant_Form27_22-02-2019.pdf 2019-02-22
42 65-che-2009 description(complete) 07-01-2010.pdf 2010-01-07
43 65-CHE-2009 FORM-2 07-01-2010.pdf 2010-01-07
43 65-CHE-2009-Form27_License_06-03-2020.pdf 2020-03-06
44 65-che-2009 form-5 07-01-2010.pdf 2010-01-07
44 65-CHE-2009-Correspondence_06-03-2020.pdf 2020-03-06

ERegister / Renewals

3rd: 11 Dec 2015

From 09/01/2011 - To 09/01/2012

4th: 11 Dec 2015

From 09/01/2012 - To 09/01/2013

5th: 11 Dec 2015

From 09/01/2013 - To 09/01/2014

6th: 11 Dec 2015

From 09/01/2014 - To 09/01/2015

7th: 11 Dec 2015

From 09/01/2015 - To 09/01/2016

8th: 11 Dec 2015

From 09/01/2016 - To 09/01/2017

9th: 29 Dec 2016

From 09/01/2017 - To 09/01/2018

10th: 04 Jan 2018

From 09/01/2018 - To 09/01/2019

11th: 31 Dec 2018

From 09/01/2019 - To 09/01/2020